Volume 125, Issue 6 , Pages 1315-1321.e9, June 2010
Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes
Background
The dynamics and balance of allergen-specific IgE, IgG4, and IgA binding might contribute to the development of tolerance in patients with cow's milk allergy (CMA). Profiling of antibody binding to cow's milk (CM) protein epitopes might help in predicting the natural history of allergy.
Objective
We sought to investigate differences in IgE, IgG4, and IgA binding to CM epitopes over time between patients with early recovery or with persisting CMA.
Methods
We studied serum samples at the time of diagnosis (mean age, 7 months), 1 year later, and at follow-up (mean age, 8.6 years) from 11 patients with persisting IgE-mediated CMA at age 8 to 9 years and 12 patients who recovered by age 3 years. We measured the binding of IgE, IgG4, and IgA antibodies to sequential epitopes derived from 5 major CM proteins with a peptide microarray–based immunoassay. We analyzed the data with a novel image-processing method together with machine learning prediction.
Results
IgE epitope–binding patterns were stable over time in patients with persisting CMA, whereas binding decreased in patients who recovered early. Binding patterns of IgE and IgG4 overlapped. Among patients who recovered early, the signal of IgG4 binding increased and that of IgE decreased over time. IgE and IgG4 binding to a panel of αs1-, αs2-, β-, and κ-casein regions predicted outcome with significant accuracy.
Conclusions
Attaining tolerance to CM is associated with decreased epitope binding by IgE and a concurrent increase in corresponding epitope binding by IgG4.
Key words: Cow's milk allergy, tolerance, epitope, IgE, IgG4, IgA
Abbreviations used: CM, Cow's milk, CMA, Cow's milk allergy, PBS-T, PBS containing 0.05% Tween 20
Supported by Helsinki University Central Hospital Research Funds, the Foundation for Pediatric Research (Finland), grant AI44326 from the National Institute of Allergy and Infectious Diseases, and a grant from the Food Allergy Initiative.
Disclosure of potential conflict of interest: E. M. Savilahti has received research support from the Foundation for Pediatric Research, Finland, and Helsinki University Central Hospital Research Funds. E. Savilahti has received research support from Helsinki University Central Hospital Research Funds. H. A. Sampson is a consultant for and holds shares in Allertein Pharmaceuticals, LLC; has received research support from the Food Allergy Initiative and the National Institute of Allergy and Infectious Diseases/National Institutes of Health; is a consultant/scientific advisor for the Food Allergy Initiative; and is a part owner of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(10)00571-3
doi:10.1016/j.jaci.2010.03.025
© 2010 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 125, Issue 6 , Pages 1315-1321.e9, June 2010
